Fusarium infections in critically Ill patients

被引:38
作者
Lionakis, MS [1 ]
Kontoyiannis, DP [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Infect Dis, Infect Control & Employee Hlth Unit 402, Houston, TX 77030 USA
关键词
Fusarium; invasive fusariosis; pneumonia; immunocompromised host; leukemia;
D O I
10.1055/s-2004-824900
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Invasive mold infections (IMIs) are significant causes of infectious mortality in immunocompromised patients, such as those with hematologic malignancies and allogeneic bone marrow transplant recipients. Of the IMIs, invasive aspergillosis is by far the most common. Nevertheless, over the past decade, other filamentous molds, such as Fusarium species, have been increasingly reported as the cause of severe IMIs in these patient populations. Herein we critically review the epidemiology, pathogenesis, clinical presentation, diagnostic methods, and therapeutic approaches for invasive fusariosis in inummocompromised hosts. We also present the key characteristics and differentiating features of invasive fusariosis and invasive aspergillosis. Current therapeutic approaches for fusariosis are suboptimal, resulting in exceedingly high mortality rates. At present, prompt diagnosis along with rapid initiation of appropriate treatment and, more importantly, reconstitution of the host immune responses are critical for a favorable outcome of this devastating opportunistic mycosis.
引用
收藏
页码:159 / 169
页数:11
相关论文
共 105 条
[1]   THE EMERGING ROLE OF FUSARIUM INFECTIONS IN PATIENTS WITH CANCER [J].
ANAISSIE, E ;
KANTARJIAN, H ;
RO, J ;
HOPFER, R ;
ROLSTON, K ;
FAINSTEIN, V ;
BODEY, G .
MEDICINE, 1988, 67 (02) :77-83
[2]   OPPORTUNISTIC MYCOSES IN THE IMMUNOCOMPROMISED HOST - EXPERIENCE AT A CANCER CENTER AND REVIEW [J].
ANAISSIE, E .
CLINICAL INFECTIOUS DISEASES, 1992, 14 :S43-S53
[3]  
ANAISSIE EJ, 1992, J INFECT DIS, V165, P1155, DOI 10.1093/infdis/165.6.1155
[4]   Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system:: A new paradigm for the epidemiology of opportunistic mold infections [J].
Anaissie, EJ ;
Kuchar, RT ;
Rex, JH ;
Francesconi, A ;
Kasai, M ;
Müller, FMC ;
Lozano-Chiu, M ;
Summerbell, RC ;
Dignani, MC ;
Chanock, SJ ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (11) :1871-1878
[5]  
[Anonymous], CLIN MYCOLOGY
[6]   Resolution of Fungemia due to Fusarium species in a patient with acute leukemia treated with caspofungin [J].
Apostolidis, J ;
Bouzani, M ;
Platsouka, E ;
Belasiotou, H ;
Stamouli, M ;
Harhalakis, N ;
Boutati, EI ;
Paniara, O ;
Nikiforakis, E .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (10) :1349-1350
[7]   Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species [J].
Arikan, S ;
Lozano-Chiu, M ;
Paetznick, V ;
Nangia, S ;
Rex, JH .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (12) :3946-3951
[8]   In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. [J].
Arikan, S ;
Lozano-Chiu, M ;
Paetznick, V ;
Rex, JH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :245-247
[9]   In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates [J].
Arikan, S ;
Lozano-Chiu, M ;
Paetznick, V ;
Rex, JH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :327-330
[10]   Topical nystatin powder in severe burns: a new treatment for angioinvasive fungal infections refractory to other topical and systemic agents [J].
Barret, JP ;
Ramzy, PI ;
Heggers, JP ;
Villareal, C ;
Herndon, DN ;
Desai, MH .
BURNS, 1999, 25 (06) :505-508